These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. New Concepts in Dopamine D Urs NM; Peterson SM; Caron MG Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841 [TBL] [Abstract][Full Text] [Related]
26. The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation. Pack TF; Orlen MI; Ray C; Peterson SM; Caron MG J Biol Chem; 2018 Apr; 293(16):6161-6171. PubMed ID: 29487132 [TBL] [Abstract][Full Text] [Related]
27. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells. Vanhauwe JF; Ercken M; van de Wiel D; Jurzak M; Leysen JE Psychopharmacology (Berl); 2000 Jul; 150(4):383-90. PubMed ID: 10958079 [TBL] [Abstract][Full Text] [Related]
31. Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases. Liu H; Ma H; Zeng X; Wu C; Acharya S; Sudan SK; Zhang X Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373182 [TBL] [Abstract][Full Text] [Related]
32. Signalling profile differences: paliperidone versus risperidone. Clarke WP; Chavera TA; Silva M; Sullivan LC; Berg KA Br J Pharmacol; 2013 Oct; 170(3):532-45. PubMed ID: 23826915 [TBL] [Abstract][Full Text] [Related]
33. Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain. Sakuma K; Komatsu H; Maruyama M; Imaichi S; Habata Y; Mori M PLoS One; 2015; 10(2):e0118510. PubMed ID: 25693194 [TBL] [Abstract][Full Text] [Related]
34. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
35. Comparative study of the molecular mechanisms underlying the G protein and β-arrestin-dependent pathways that lead to ERKs activation upon stimulation by dopamine D Liu H; Acharya S; Sudan SK; Hu L; Wu C; Cao Y; Li H; Zhang X FEBS J; 2023 Nov; 290(21):5204-5233. PubMed ID: 37531324 [TBL] [Abstract][Full Text] [Related]
36. Phosphoproteomic Analysis of Dopamine D2 Receptor Signaling Reveals Interplay of G Protein- and β-Arrestin-Mediated Effects. Wenk D; Khan S; Ignatchenko V; Hübner H; Gmeiner P; Weikert D; Pischetsrieder M; Kislinger T J Proteome Res; 2023 Jan; 22(1):259-271. PubMed ID: 36508580 [TBL] [Abstract][Full Text] [Related]
38. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741 [TBL] [Abstract][Full Text] [Related]
39. Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis. Zhou Z; Liao JM; Zhang P; Fan JB; Chen J; Liang Y Protein Cell; 2011 Nov; 2(11):899-905. PubMed ID: 22180089 [TBL] [Abstract][Full Text] [Related]
40. G protein-coupled receptor kinase regulates dopamine D3 receptor signaling by modulating the stability of a receptor-filamin-beta-arrestin complex. A case of autoreceptor regulation. Kim KM; Gainetdinov RR; Laporte SA; Caron MG; Barak LS J Biol Chem; 2005 Apr; 280(13):12774-80. PubMed ID: 15687500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]